The nitrone compound OKN-007, which targets the TGFB1 pathway as well as VEGFR2a and HIF-1α, is currently being investigated in a handful of clinical trials in newly diagnosed and recurrent GBM (NCT01672463, NCT00561374, and NCT04388475). This evidence concerns the gene HIF1A and glioblastoma.